Cantor Fitzgerald Reiterates Overweight on Crinetics Pharmaceuticals, Maintains $50 Price Target
Portfolio Pulse from Benzinga Newsdesk
Cantor Fitzgerald analyst Josh Schimmer has reiterated an Overweight rating on Crinetics Pharmaceuticals (CRNX) and maintained a $50 price target.
February 02, 2024 | 2:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald reaffirms an Overweight rating on Crinetics Pharmaceuticals with a $50 price target.
The reiteration of an Overweight rating and a $50 price target by a reputable analyst like Josh Schimmer from Cantor Fitzgerald could instill confidence among investors and potentially lead to a positive short-term price movement for CRNX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90